Skip to main content
Explore URMC

URMC Logo

menu
URMC / Labs / Maquat Lab / News

News

20172016201520142013 Archive

Lynne Maquat Delivers Harvey Society Lecture at Rockefeller University

Tuesday, November 7, 2017

Maquat Photo

Lynne E. Maquat, Ph.D., the J. Lowell Orbison Endowed Chair and Professor in the Department of Biochemistry and Biophysics and Director of the Center for RNA Biology gave a Harvey Society Lecture on October 19 at The Rockefeller University in New York City. The lecture series is one of the most prestigious in the country and the lecturers, who are selected by the Harvey Society's leadership council, are leading biomedical researchers from around the world.

Maquat discussed her career path and the discovery of nonsense-mediated mRNA decay (NMD), which she first described for humans in 1981. NMD is a cellular quality control mechanism that derails the production of unwanted proteins in the body that can disrupt normal processes and initiate disease. Maquat is known around the world for her work on NMD, which is critically important in both normal and disease states. UR President Joel Seligman and URMC CEO and SMD Dean Mark Taubman attended the lecture.

Founded in 1905, the Harvey Society sponsors seven lectures annually that are open to the public and are attended by hundreds of scientists from New York City and the surrounding areas. The Harvey Lectures are one of the great traditions in New York science and they are a place where scientists from different institutions meet regularly.

URMC Scientist Lynne Maquat Elected to National Academy of Medicine

Monday, October 16, 2017

Lynne E. Maquat, Ph.D., an internationally recognized researcher who studies what happens in our cells during disease, has been elected to the National Academy of Medicine. The honor is akin to an actor receiving an Emmy for an outstanding performance; current members of the Academy elected Maquat for her exceptional research in the field of RNA biology. The accolade places her amongst an elite group of scientists and physicians who have made significant contributions to health and medicine.

In studying RNA, a close cousin to DNA, Maquat has discovered intricate cellular processes that influence normal genes, as well as genes involved in a wide range of diseases. Her findings are leading to the development of new treatment approaches for everything from cancer and heart disease, to intellectual and developmental disabilities and other neurologic disorders.

“Lynne is at the forefront of a movement to transform our increasing understanding of RNA biology into promising therapies for virtually all disease processes,” said Mark B. Taubman, M.D., CEO of the University of Rochester Medical Center and Dean of the University of Rochester School of Medicine and Dentistry. “She is an incredible asset to the University and will undoubtedly bring a wealth of valuable experience and knowledge to the National Academy of Medicine.”

Formerly called the Institute of Medicine, the National Academy of Medicine is an independent organization of professionals from diverse fields that advises the nation and the international community on issues in health, medicine and related policy. For example, in 2016 the Academy released a report calling for more and better research into ovarian cancer, one of the deadliest cancers, and recently issued a report detailing how physicians can help combat America’s opioid crisis.

The J. Lowell Orbison Endowed Chair and Professor of Biochemistry & Biophysics and of Oncology at the University of Rochester School of Medicine and Dentistry, Maquat is also an elected member of the National Academy of Sciences and the American Academy of Sciences. She was the first individual from upstate New York to receive the prestigious Canada International Gairdner Award, the country’s top award for excellence in biomedical research, which she won in 2015.

The National Institutes of Health has continuously funded Maquat’s research for the past 34 years and she’s published more than 150 papers and reviews. She is the founding director of the University of Rochester Center for RNA Biology and founding chair of the Graduate Women in Science program. She’s committed countless hours to mentoring the next generation of researchers and advocating for young women in the sciences.

When she is formally inducted into the National Academy of Medicine in October 2018, Maquat will join four other active Rochester faculty members: Seymour I. Schwartz in the Department of Surgery: Elizabeth R. McAnarney in Pediatrics; Paul S. Frame in Family Medicine; and Robert C. Griggs in Neurology.

Read More: URMC Scientist Lynne Maquat Elected to National Academy of Medicine

Maquat Honored with FASEB Award, Featured on People Behind the Science Podcast

Friday, August 25, 2017

Maquat Photo

Dr. Lynne Maquat, J. Lowell Orbison Endowed Chair and Professor of Biochemistry and Biophysics in the School of Medicine and Dentistry, Director of the Center for RNA Biology, and Chair of Graduate Women in Science at the University of Rochester was recently featured on the podcast, People Behind the Science.

Lynne discusses her mentors and career milestones, and offers advice to junior scientists. Maquat recently received the Federation of American Societies for Experimental Biology's Excellence in Science Award, which recognizes women who have made outstanding contributions to science through research discoveries and by training the next generation of scientists.

The entire interview can be listened to for free on iTunes.

Read More: Maquat Honored with FASEB Award, Featured on People Behind the Science Podcast

Study: A New Way to Slow Cancer Cell Growth

Friday, May 26, 2017

cells divide

Cells grow and divide during the cell cycle

Cancer is an extremely complex disease, but its definition is quite simple: the abnormal and uncontrollable growth of cells. Researchers from the University of Rochester’s Center for RNA Biology have identified a new way to potentially slow the fast-growing cells that characterize all types of cancer. The findings, reported today in the journal Science and funded by the National Institutes of Health, were made in kidney and cervical cancer cells in the laboratory and are a long way from being applied in people. But, they could be the basis of a treatment option in the future, the authors said.

Cancer: The Cell Cycle Gone Wrong

All cells go through the “cell cycle,” a series of events that culminate in orderly cell growth and division. In cancer, the cell cycle is out of whack; cells divide without stopping and invade surrounding tissues.

Lynne Maquat

Lynne Maquat, Ph.D.

Researchers identified a protein called Tudor-SN that is important in the “preparatory” phase of the cell cycle – the period when the cell gets ready to divide. When scientists eliminated this protein from cells, using the gene editing technology CRISPR-Cas9, cells took longer to gear up for division. The loss of Tudor-SN slowed the cell cycle.

“We know that Tudor-SN is more abundant in cancer cells than healthy cells, and our study suggests that targeting this protein could inhibit fast-growing cancer cells,” said Reyad A. Elbarbary, Ph.D., lead study author and research assistant professor in the Center for RNA Biology and the department of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry.

Elbarbary, who works in the laboratory of senior study author Lynne E. Maquat, Ph.D., a world-renowned expert in RNA biology, adds that there are existing compounds that block Tudor-SN that could be good candidates for a possible therapy.

Putting the Brakes on Cell Growth

Maquat’s team discovered that Tudor-SN influences the cell cycle by controlling microRNAs, molecules that fine tune the expression of thousands of human genes.

When Tudor-SN is removed from human cells, the levels of dozens of microRNAs go up. Boosting the presence of microRNAs puts the brakes on genes that encourage cell growth. With these genes in the “off” position, the cell moves more slowly from the preparatory phase to the cell division phase.

“Because cancer cells have a faulty cell cycle, pursuing factors involved in the cell cycle is a promising avenue for cancer treatment,” noted Maquat, director of the Center for RNA Biology and the J. Lowell Orbison Endowed Chair and professor of Biochemistry and Biophysics.

Maquat, who also holds an appointment in the Wilmot Cancer Institute, and Elbarbary have filed a patent application for methods targeting Tudor-SN for the treatment and prevention of cancer. Research next steps include understanding how Tudor-SN works in concert with other molecules and proteins so that scientists can identify the most appropriate drugs to target it.

Keita Miyoshi, Ph.D., staff scientist in Maquat’s lab, served as lead study author with Elbarbary. Jason R. Myers and John M. Ashton, Ph.D. from the UR Genomics Research Center played an instrumental role in the study analysis.

"Read More: Study: A New Way to Slow Cancer Cell Growth

Maquat Receives Lifetime Achievement Award in Science from International RNA Society

Tuesday, February 7, 2017

Photo of Lynne Maquat

Lynne E. Maquat, Ph.D. has spent her career unraveling what happens in our cells during disease, making seminal contributions to our understanding of RNA’s role in sickness and in health. She’s also committed countless hours to mentoring the next generation of researchers and advocating for young women in the sciences. For these exceptional efforts, she’s receiving the 2017 Lifetime Achievement Award in Science from the international RNA Society.

The J. Lowell Orbison Endowed Chair and Professor in the Department of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry, Maquat began her professional career studying inherited anemias. She discovered a quality control process that blocks the creation of toxic proteins that cause disease. Known as nonsense-mediated mRNA decay or NMD, this process plays a part in one third of all inherited diseases, such as cystic fibrosis and muscular dystrophy, and one third of all acquired diseases, including a number of cancers.

“This award recognizes Lynne’s pioneering contributions to understanding the mechanisms of RNA, as well as her outstanding leadership, support and commitment to our field, including her role as a model for new generations of scientists,” said Juan Valcarcel Juarez, current president of the RNA Society, who works at the Centre for Genomic Regulation in Barcelona, Spain.

James McSwiggen, CEO of the RNA Society, added, “I can’t imagine a more appropriate choice of awardee.”

Read More: Maquat Receives Lifetime Achievement Award in Science from International RNA Society